The equal potency of therapeutic PDE4 inhibition compared to the FDA‐approved drugs in a model of lung fibrosis that shares pathogenic features with the human disease serves as strong motivation to investigate the efficacy of roflumilast or Compound 1 in patients with IPF. This evidence concerns the gene PDE4A and idiopathic pulmonary fibrosis.